Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2022 16:05 ET | Source: Otonomy, Inc.

Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported...
October 13, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss

Higher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from baselineLack of activity compared to 0.3 mg dose evaluated in prior studies may be due to a complex...
August 01, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus

OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepointsCompany to discontinue development of OTO-313 and implement other...
July 18, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update

SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
May 18, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy to Participate in the H.C. Wainwright Global Investment Conference

SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its...
May 12, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
May 02, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate Update

SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will...
April 20, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss

Clinical benefit again observed for OTO-413 versus placebo for multiple efficacy endpoints based on responder analysis at both Days 57 and 85 Results support clinical activity and tolerability...
February 28, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
February 25, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy to Host Virtual Investor R&D Event on March 22, 2022

SAN DIEGO, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...

Next Page keyboard_arrow_right